10x Genomics, Inc. (TXG) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone. Welcome to day three of the Morgan Stanley Global Healthcare Conference. My name is Edmund Tu, and I work on the Life Science Tools team here at Morgan Stanley. And it's my pleasure to be hosting 10X Genomics today. And representing the company, we have co-founder, CEO, Mr. Serge Seixonal. Thank you for joining us. Thank you for having me. Before we start, I'd just like to remind everyone in the audience, important disclosure information can be found on our research disclosure website at morganstanley.com forward slash research disclosures. If you have any questions, please reach out to your MS sales rep. And with that, maybe to kick things off, Serge, it's been a unique year with various policy and macro headwinds impacting your end market. Understanding things have changed meaningfully since the start of the year, how would you sum up the past nine months for 10X Genomics, and what would you say are your proudest achievements in this challenging market? Yeah, it has certainly been a pretty eventful year. We started that with really good momentum and of course there has been a lot of news flow, a lot of changes in the macro environment. And I would say the high level, the things I would want to emphasize is just how proud I am of the team and their execution through all the things that kept hitting them and all the challenges and all the changes in the environment and that's across the board. the people in the field, the sales team dealing with the customers and all the issues and all the problems they're facing, the operations teams, R&D, G&A, across the whole company really coming together and navigating, persevering through this environment. In terms of the substantive achievements of the team, there's been a whole number. We finished our ...